Eupraxia Pharmaceuticals (EPRX) Consolidated Net Income (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Consolidated Net Income for 4 consecutive years, with -$12.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 86.74% year-over-year to -$12.6 million; the TTM figure through Mar 2026 stood at -$44.4 million (down 119.11% YoY), while the FY2025 annual figure was -$38.6 million, down 49.96% from the prior year.
• Consolidated Net Income improved to -$12.6 million in Q1 2026 per EPRX's latest filing, from -$16.7 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$4.0 million in Q1 2023 and bottomed at -$16.7 million in Q4 2025.
• Historically, Consolidated Net Income has averaged -$8.3 million across 4 years, with a median of -$6.8 million in 2025.
• On a YoY basis, Consolidated Net Income climbed as much as 6.32% in 2025 and fell as far as 121.9% in 2025.
• Eupraxia Pharmaceuticals' Consolidated Net Income stood at -$4.0 million in 2023, then slumped by 90.35% to -$7.5 million in 2024, then slumped by 121.9% to -$16.7 million in 2025, then increased by 24.43% to -$12.6 million in 2026.
• Business Quant data shows EPRX's Consolidated Net Income at -$12.6 million in Q1 2026, -$16.7 million in Q4 2025, and -$6.4 million in Q3 2025.